NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT04283669 2026-03-13
NF110
University of Alabama at Birmingham
Phase 2 Completed
NCT01121588 2025-01-23
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Pfizer
Phase 1 Terminated
NCT01606878 2024-01-05
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT02270034 2022-03-10
Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
Grupo Español de Investigación en Neurooncología
Phase 1 Completed
NCT00939770 2020-06-09
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Children's Oncology Group
Phase 1/2 Completed
NCT01644773 2019-03-22
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn